CFO
Vivoryon Therapeutics N.V.
Equibles does not estimate personal net worth.
Marcus Irsfeld is recorded as CFO at Vivoryon Therapeutics N.V.. Marcus Irsfeld has spoken on 1 earnings call across 1 company, most recently for Vivoryon Therapeutics N.V. on April 23, 2026. Vivoryon Therapeutics N.V. is classified in the Biotechnology industry within the Healthcare sector.
“I will now walk you through the financial figures for the 2025 business year. Research and development expenses in 2025 amounted to 4.3 million euros compared to 14.1 million euros in 2024.”
Vivoryon Therapeutics N.V.
CFO
Transcript header (unverified)
Vivoryon Therapeutics N.V.
Biotechnology · Healthcare
CFO
Full Year Results 2025
Vivoryon Therapeutics N.V.
